When economic conditions improve, the Company will reevaluaterehabilitation projects currently on hold and will continue to consideradditional properties contemplated in the Company`s acquisition strategy. Investors and others who base themselves onthe Corporation’s forward-looking statements should carefully considerthe above factors as well as the uncertainties they represent and therisk they entail. rSmart`s Kualisupport program is tailored to be modular so institutions can tailor a supportprogram specific to their needs at the most economical price. In addition, Lincoln disclaims any obligation to update anyforward-looking statements to reflect events or circumstances that occur afterthe date of the release.SOURCELincoln Financial GroupInvestor Relations, Jim Sjoreen, +1-484-583-1420, ,or Media Relations, Laurel O’Brien, +1-484-583-1735, . The decline from March 31, 2009 was primarily due to a greater volume ofshipments to customers at the end of the quarter for which payments have been orare expected to be received in full in the second quarter of fiscal 2009. These risks and uncertainties include that the Company may notreceive all or any funds allocated under the DoD Appropriation, that BioFoammay not prove safe or effective for its intended uses, and that BioFoamdevelopment may not result in a commercial product on the time tableanticipated, or at all.For additional risks impacting the Company’sbusiness, see the Risk Factors section of the Company’s Annual Report onForm-10-K for the year ended December 31, 2008 and the Company’s subsequentForm 10-Q filings.The Company does not undertake to update itsforward-looking statements.For additional information about the Company, visit CryoLife’s Web Site: http:// Contacts:D.
The Company intends tovigorously defend these claims, however there is no assurance that itwill be successful.(b) The Company is subject to other lawsuits from time to time which arenot disclosed on the grounds that they are not believed to be material.TRANSACTIONS WITH RELATED PARTIESOne of the directors of the Company is a partner of an affiliate ofBlake, Cassels & Graydon LLP. ATLANTA, GA, Aug 20 (MARKET WIRE) — LIGATT Security International (PINKSHEETS: LGTT) CEO, Gregory Evans,announced that the company has had an unprecedented amount of exposure,web traffic and unique website visitors as the result of its nationalmedia campaign which launched in July. Thus, the housing market is not only varying in performanceacross metropolitan areas but there is almost more variation within each ofthe metropolitan areas,” said Dr Geoffrey J.D. The test on average delivered 15.6 millisieverts of radiation per dose, and accounted for more than 22 percent of the total radiation exposure among people in the study, more than any other test.For people living in the United States, the normal expected radiation dose from chemicals in the ground or flying in an airplane is 3 millisieverts a year.Despite its widespread use, there is no evidence that the test saves lives, Dr.
Spotted Canary is about everything crafting, whether it is scrapbooking, jewelrymaking, kids projects, paper crafting, needle work or crafts in general.EKSuccess Brands worked with Ektron Certified partner PINT to build the SpottedCanary community on CMS400.NET and leverage Ektron`s Web 2.0 and social mediafeatures to enable interaction and collaboration between members. VANCOUVER, BRITISH COLUMBIA, Sep 02 (MARKET WIRE) — Canadian Zinc Corporation (TSX: CZN)(OTCBB: CZICF) announces that it iscommencing a diamond drill exploration program on the Tuvatu Gold Project(“Tuvatu”) on the island of Viti Levu, in Fiji.The diamond drill, contracted from Radial Drilling Fiji Pty Ltd., hasbeen mobilized to the Tuvatu property. KMP has demonstrated access to both debt and equity capital markets in 2009 andhas adequate liquidity to manage its capital needs, including the continuingcommitment from Kinder Morgan Inc. Coblin, 561-674-9520orPearl Group Advisors, Inc.Public Relations, 954-232-5363orBig Apple Consulting USA, Inc.Investor Relations, 407-389-5900Copyright Business Wire 2009. develops targeted anticancer therapeutics using its expertise incancer biology, monoclonal antibodies and the creation and attachment of potentcell-killing agents.